|
1
|
Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM.
|
J Biol Chem
|
2004
|
2.33
|
|
2
|
Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells.
|
Nat Biotechnol
|
2002
|
1.48
|
|
3
|
CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors.
|
Mol Ther Nucleic Acids
|
2013
|
1.45
|
|
4
|
Multivalent antibodies: when design surpasses evolution.
|
Trends Biotechnol
|
2010
|
1.28
|
|
5
|
Antibody engineering: facing new challenges in cancer therapy.
|
Acta Pharmacol Sin
|
2005
|
1.14
|
|
6
|
In vivo tumor targeting and imaging with engineered trivalent antibody fragments containing collagen-derived sequences.
|
PLoS One
|
2009
|
1.02
|
|
7
|
Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery?
|
Hum Gene Ther
|
2002
|
1.00
|
|
8
|
Antibodies and gene therapy: teaching old 'magic bullets' new tricks.
|
Trends Immunol
|
2004
|
0.99
|
|
9
|
Selection of functional human antibodies from retroviral display libraries.
|
Nucleic Acids Res
|
2005
|
0.97
|
|
10
|
A novel cell binding site in the coiled-coil domain of laminin involved in capillary morphogenesis.
|
EMBO J
|
2003
|
0.94
|
|
11
|
Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells.
|
J Immunol
|
2003
|
0.94
|
|
12
|
The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategies.
|
J Biol Chem
|
2010
|
0.94
|
|
13
|
Enhanced antiangiogenic therapy with antibody-collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events.
|
Int J Cancer
|
2006
|
0.92
|
|
14
|
Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth.
|
Cancer Gene Ther
|
2005
|
0.91
|
|
15
|
Functional improvement of antibody fragments using a novel phage coat protein III fusion system.
|
Biochem Biophys Res Commun
|
2002
|
0.90
|
|
16
|
Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies.
|
Proc Natl Acad Sci U S A
|
2013
|
0.90
|
|
17
|
Lymphocyte display: a novel antibody selection platform based on T cell activation.
|
PLoS One
|
2009
|
0.88
|
|
18
|
Development of a computer-assisted high-throughput screening platform for anti-angiogenic testing.
|
Microvasc Res
|
2002
|
0.86
|
|
19
|
The heterotrimeric laminin coiled-coil domain exerts anti-adhesive effects and induces a pro-invasive phenotype.
|
PLoS One
|
2012
|
0.85
|
|
20
|
Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C.
|
Biochem J
|
2005
|
0.83
|
|
21
|
Virotherapy, gene transfer and immunostimulatory monoclonal antibodies.
|
Oncoimmunology
|
2012
|
0.83
|
|
22
|
Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab.
|
Med Oncol
|
2013
|
0.83
|
|
23
|
Antibody engineering, virus retargeting and cellular immunotherapy: one ring to rule them all?
|
Curr Gene Ther
|
2005
|
0.82
|
|
24
|
Antibody gene therapy: getting closer to clinical application?
|
Curr Gene Ther
|
2013
|
0.81
|
|
25
|
Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I.
|
Immunology
|
2006
|
0.80
|
|
26
|
Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein.
|
Cancer Gene Ther
|
2002
|
0.80
|
|
27
|
The extracellular matrix: a new turn-of-the-screw for anti-angiogenic strategies.
|
Trends Mol Med
|
2003
|
0.80
|
|
28
|
Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells.
|
Cancer Gene Ther
|
2005
|
0.79
|
|
29
|
The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.
|
Mol Ther
|
2012
|
0.78
|
|
30
|
Basement membrane-rich organoids with functional human blood vessels are permissive niches for human breast cancer metastasis.
|
PLoS One
|
2013
|
0.77
|
|
31
|
In vivo selection of tumor-specific antibodies.
|
Oncotarget
|
2013
|
0.76
|
|
32
|
Generation of non-permissive basement membranes by anti-laminin antibody fragments produced by matrix-embedded gene-modified cells.
|
Cancer Immunol Immunother
|
2003
|
0.76
|
|
33
|
Adenovirus E1a protein enhances the cytotoxic effects of the herpes thymidine kinase-ganciclovir system.
|
Cancer Gene Ther
|
2003
|
0.76
|
|
34
|
Comment on "Production of multivalent protein binders using a self-trimerization collagen-like peptide scaffold".
|
FASEB J
|
2008
|
0.75
|
|
35
|
Functionally fused antibodies--a novel adjuvant fusion system.
|
J Immunol Methods
|
2008
|
0.75
|
|
36
|
Antibody-based antiangiogenic cancer therapy.
|
Expert Opin Ther Targets
|
2005
|
0.75
|
|
37
|
Establishment of an immortalized PARP-1-/- murine endothelial cell line: a new tool to study PARP-1 mediated endothelial cell dysfunction.
|
J Cell Biochem
|
2005
|
0.75
|